General description
  INN
  Vincristine
ATC codes
  
Medicine type
  Chemical agent
EML status history
  
    First added in 1977
     
      (TRS
        615)
         
      for 
        Unspecified malignant neoplasms of ill-defined or unspecified sites
      
      
  
    Added in 2011
     
      (TRS
        965)
         
      for 
        Lymphoid leukaemia, not elsewhere classified
      
      
  
    Added in 2011
     
      (TRS
        965)
         
      for 
        Malignant neoplasms of kidney, except renal pelvis
      
      
  
    Added in 2011
     
      (TRS
        965)
         
      for 
        Burkitt lymphoma including Burkitt leukaemia
      
      
  
    Added in 2015
     
      (TRS
        994)
         
      for 
        Rhabdomyosarcoma primary site
      
      
  
    Added in 2015
     
      (TRS
        994)
         
      for 
        Kaposi sarcoma of unspecified primary site
      
      
  
    Added in 2015
     
      (TRS
        994)
         
      for 
        Retinoblastoma
      
      
  
    Added in 2015
     
      (TRS
        994)
         
      for 
        Diffuse large B-cell lymphomas
      
      
  
    Added in 2015
     
      (TRS
        994)
         
      for 
        Follicular lymphoma
      
      
  
    Added in 2015
     
      (TRS
        994)
         
      for 
        Malignant trophoblastic neoplasms of placenta
      
      
  
    Added in 2015
     
      (TRS
        994)
         
      for 
        Hodgkin lymphoma
      
      
  
    Added in 2015
     
      (TRS
        994)
         
      for 
        Ewing sarcoma of bone and articular cartilage of unspecified sites
      
      
  
    Removed in 2015
     
      (TRS
        994)
         
      for 
        Unspecified malignant neoplasms of ill-defined or unspecified sites
      
      
  
    Added in 2021
     
      (TRS
        1035)
         
      for 
        Other specified gliomas of brain
      
      
  
    Added in 2023
     
      (TRS
        1049)
         
      for 
        Langerhans cell histiocytosis
      
      
Wikipedia
  
DrugBank
  
Recommendations
  
          Section
        
        Cytotoxic medicines
      - Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
        Indications
      
            
                              
            Rhabdomyosarcoma primary site
          
                              
            Diffuse large B-cell lymphomas
          
                              
            Malignant trophoblastic neoplasms of placenta
          
                              
            Hodgkin lymphoma
          
                              
            Kaposi sarcoma of unspecified primary site
          
                              
            Follicular lymphoma
          
                              
            Retinoblastoma
          
                              
            Ewing sarcoma of bone and articular cartilage of unspecified sites
          
                              
            Malignant neoplasms of kidney, except renal pelvis
          
                              
            Lymphoid leukaemia, not elsewhere classified
          
                              
            Burkitt lymphoma including Burkitt leukaemia
          
                              
            Unspecified malignant neoplasms of ill-defined or unspecified sites
          
                              
            Other specified gliomas of brain
          
                              
            Langerhans cell histiocytosis